On November 2, 2026, German healthcare company Fresenius SE announced a partnership with China's WuXi Biologics, securing exclusive access to up to 37 biosimilar candidates over the next decade. The deal targets over €370 billion in expiring originator drug sales and could expand Fresenius's portfolio to 66 molecules. Fresenius shares rose up to 3% in Frankfurt, while CEO Michael Sen emphasized contract flexibility amid scrutiny of WuXi AppTec's inclusion on a U.S. Pentagon military list.
Terms of the biosimilars deal
- ▪Fresenius SE agreed to a pay-as-you-go structure for its biosimilars development agreement with WuXi Biologics, allowing Fresenius SE flexibility to halt individual biosimilar programs if necessary
- ▪The biosimilars development deal with WuXi Biologics could expand the total molecule portfolio at Fresenius SE from 29 to as many as 66 by the next decade
- ▪Fresenius SE signed a biosimilars development agreement, gaining exclusive access to up to 37 biosimilar candidates from China-based WuXi Biologics
- ▪Fresenius SE's biosimilars development agreement with WuXi Biologics covers candidates across 13 therapeutic areas, including monoclonal and bispecific antibodies, antibody-drug conjugates, and fusion proteins, addressing over €370 billion in originator sales
WuXi Biologics corporate background
- ▪WuXi Biologics was spun off from WuXi AppTec in 2017 as a contract developer and manufacturer for brand-name drugmakers
- ▪Fresenius SE Chief Executive Officer Michael Sen responded to questions regarding WuXi AppTec being listed on a U.S. Pentagon list of Chinese military-linked firms by noting that WuXi Biologics is a separately listed company
Story comments
Loading comments…